<?xml version="1.0" encoding="UTF-8"?>
<p>Besides, other forms of ZIKV vaccine, such as protein based subunit vaccine (
 <xref rid="B122" ref-type="bibr">Medina et al., 2018</xref>; 
 <xref rid="B124" ref-type="bibr">Metz et al., 2019</xref>; 
 <xref rid="B170" ref-type="bibr">Slon-Campos et al., 2019</xref>) and live attenuated Zika vaccines (
 <xref rid="B149" ref-type="bibr">Richner et al., 2017b</xref>; 
 <xref rid="B202" ref-type="bibr">Xie et al., 2018</xref>; 
 <xref rid="B166" ref-type="bibr">Shan et al., 2019</xref>) are also under development at the pre-clinical stage. Considering the cross-reactivity and ADE between ZIKV and DENV, newly developed ZIKV vaccine should also be tested for DENV enhancement activity. This additional requirement will likely to be a huge obstacle for both ZIKV and DENV vaccines.
</p>
